New drug duo targets Hard-to-Treat HER2 cancers
NCT ID NCT04585958
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 30 times
Summary
This early-phase study tests two drugs together—DS-8201a and olaparib—in people with advanced HER2-positive cancers that have spread or can't be removed. The goal is to find the safest dose and see if the combination can shrink tumors. About 55 adults with certain solid tumors or platinum-resistant ovarian cancer will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MALIGNANT SOLID NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic Hospital in Arizona
ACTIVE_NOT_RECRUITINGPhoenix, Arizona, 85054, United States
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact
Contact Phone: •••-•••-••••
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact Phone: •••-•••-••••
-
University of Pittsburgh Cancer Institute (UPCI)
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.